Phase 1 inpatient study of the safety and immunogenicity of live influenza A vaccine H7N3 (6-2) AA ca recombinant (A/Chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca), a live attenuated virus vaccine candidate for the prevention of avian influenza H7N3 infection in the event of a pandemic.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Influenza A virus vaccine H7N3 (Primary)
- Indications Influenza A virus infections
- Focus Adverse reactions; Pharmacodynamics
- 18 May 2015 Biomarkers information updated
- 16 Jan 2008 Status changed from recruiting to completed.
- 27 Aug 2007 New trial record.